Why Bristol-Myers Squibb Company (BMY) Is Among the Best Pharma Stocks to Invest in Amid the Domestic Manufacturing Boom
From Yahoo Finance: 2025-05-13 17:05:00
A look at Bristol-Myers Squibb’s position among the best pharma stocks in the US manufacturing boom. Pharmaceutical ingredient production has shifted to China over the years, with the US importing $203 billion in pharmaceutical products in 2023. President Trump’s executive order aims to incentivize domestic drug manufacturing, streamlining approvals and inspections.
The order also directs the EPA to accelerate construction related to drug manufacturing. However, potential tariffs on imported medicines have led to mixed reactions from pharmaceutical companies. Reshoring manufacturing could strengthen the drug supply chain but may increase prices and production costs. Bristol-Myers Squibb plans to invest $40 billion in the US over five years to enhance radiopharmaceutical manufacturing and innovation.
Piper Sandler raised Bristol-Myers Squibb’s price target, anticipating growth based on Q1 earnings. While BMY ranks fifth among the best pharma stocks, some believe AI stocks offer higher returns in a shorter timeframe. If you’re looking for promising AI stocks, consider those with significant upside potential at a low valuation.